The Russian Ministry of Health announced this Friday that it began tests of the coronavirus vaccine, Sputnik V, in volunteers over 60 years old.
According to the head of that portfolio, Mikhail Murashko, the study aims to broaden the spectrum of application of the drug in the elderly population, susceptible to evolve with more aggressive symptoms if they become infected with Covid-19.
The Sputnik V vaccine was developed by the Gamaleya National Research Center for Epidemiology and Microbiology in Moscow, registered on August 11, and is currently in its third phase of trials.
The clinical trials involve some 40,000 volunteers, although more than 60,000 people registered in the Russian capital to participate in them. Sputnik V vaccine involves the introduction of two components of the drug with an interval of three weeks.
This week, Russian President Vladimir Putin announced the registration of another national coronavirus vaccine developed by the state research center Vector. Your post-registration testing will begin shortly.
In addition to these two products, scientists at the Chumakov Center for Research and Development of Immunobiological Preparations of the Russian Academy of Sciences are working to create a live vaccine. More than 40 countries have already expressed interest in obtaining the Sputnik V vaccine.